Phase II trial of etoposide, doxorubicin, and cisplatin combination in advanced measurable gastric cancer: An Eastern Cooperative Oncology Group study

J. L. Clark, O. Kucuk*, D. S. Neuberg, A. B. Benson, S. G. Taylor IV, K. J. Pandya, E. G. Mansour, H. O. Douglass, D. G. Haller

*Corresponding author for this work

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

A phase II study was performed to determine the efficacy and toxicity of the etoposide, doxorubicin, cisplatin (EAP) regimen in the treatment of patients with advanced measurable gastric cancer in a multi-institutional cooperative group setting. Thirty-one evaluable patients with advanced measurable gastric adenocarcinoma were treated with etoposide 120 mg/m2 on days 3, 4, and 5, doxorubicin 20 mg/m2 on days 1 and 8, and cisplatin 40 mg/m2 on days 2 and 9. The treatment was repeated every 28 days. Objective responses were seen in 7 (23%) patients, all achieving partial remissions. Median survival was 9 months for the entire group. Toxicity was mostly hematologic, with grade 3 leukopenia in 26% and grade 4 leukopenia in 55% of the patients. There were 4 treatment-related deaths that were attributable to severe leukopenia and sepsis. Because of the high toxicity and moderate response rate, this regimen is not superior to other less toxic regimens and cannot be recommended for the treatment of advanced gastric cancer outside of an investigational protocol.

Original languageEnglish (US)
Pages (from-to)318-324
Number of pages7
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume18
Issue number4
DOIs
StatePublished - Jan 1 1995

Fingerprint

Etoposide
Doxorubicin
Cisplatin
Stomach Neoplasms
Leukopenia
Poisons
Therapeutics
Sepsis
Stomach
Adenocarcinoma
Survival

Keywords

  • Advanced gastric cancer
  • Cisplatin
  • Combination chemotherapy
  • Doxorubicin
  • Etoposide

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Clark, J. L. ; Kucuk, O. ; Neuberg, D. S. ; Benson, A. B. ; Taylor IV, S. G. ; Pandya, K. J. ; Mansour, E. G. ; Douglass, H. O. ; Haller, D. G. / Phase II trial of etoposide, doxorubicin, and cisplatin combination in advanced measurable gastric cancer : An Eastern Cooperative Oncology Group study. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 1995 ; Vol. 18, No. 4. pp. 318-324.
@article{c8ea793bdb684ef0a2ec10b55678297a,
title = "Phase II trial of etoposide, doxorubicin, and cisplatin combination in advanced measurable gastric cancer: An Eastern Cooperative Oncology Group study",
abstract = "A phase II study was performed to determine the efficacy and toxicity of the etoposide, doxorubicin, cisplatin (EAP) regimen in the treatment of patients with advanced measurable gastric cancer in a multi-institutional cooperative group setting. Thirty-one evaluable patients with advanced measurable gastric adenocarcinoma were treated with etoposide 120 mg/m2 on days 3, 4, and 5, doxorubicin 20 mg/m2 on days 1 and 8, and cisplatin 40 mg/m2 on days 2 and 9. The treatment was repeated every 28 days. Objective responses were seen in 7 (23{\%}) patients, all achieving partial remissions. Median survival was 9 months for the entire group. Toxicity was mostly hematologic, with grade 3 leukopenia in 26{\%} and grade 4 leukopenia in 55{\%} of the patients. There were 4 treatment-related deaths that were attributable to severe leukopenia and sepsis. Because of the high toxicity and moderate response rate, this regimen is not superior to other less toxic regimens and cannot be recommended for the treatment of advanced gastric cancer outside of an investigational protocol.",
keywords = "Advanced gastric cancer, Cisplatin, Combination chemotherapy, Doxorubicin, Etoposide",
author = "Clark, {J. L.} and O. Kucuk and Neuberg, {D. S.} and Benson, {A. B.} and {Taylor IV}, {S. G.} and Pandya, {K. J.} and Mansour, {E. G.} and Douglass, {H. O.} and Haller, {D. G.}",
year = "1995",
month = "1",
day = "1",
doi = "10.1097/00000421-199508000-00010",
language = "English (US)",
volume = "18",
pages = "318--324",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

Phase II trial of etoposide, doxorubicin, and cisplatin combination in advanced measurable gastric cancer : An Eastern Cooperative Oncology Group study. / Clark, J. L.; Kucuk, O.; Neuberg, D. S.; Benson, A. B.; Taylor IV, S. G.; Pandya, K. J.; Mansour, E. G.; Douglass, H. O.; Haller, D. G.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 18, No. 4, 01.01.1995, p. 318-324.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Phase II trial of etoposide, doxorubicin, and cisplatin combination in advanced measurable gastric cancer

T2 - An Eastern Cooperative Oncology Group study

AU - Clark, J. L.

AU - Kucuk, O.

AU - Neuberg, D. S.

AU - Benson, A. B.

AU - Taylor IV, S. G.

AU - Pandya, K. J.

AU - Mansour, E. G.

AU - Douglass, H. O.

AU - Haller, D. G.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - A phase II study was performed to determine the efficacy and toxicity of the etoposide, doxorubicin, cisplatin (EAP) regimen in the treatment of patients with advanced measurable gastric cancer in a multi-institutional cooperative group setting. Thirty-one evaluable patients with advanced measurable gastric adenocarcinoma were treated with etoposide 120 mg/m2 on days 3, 4, and 5, doxorubicin 20 mg/m2 on days 1 and 8, and cisplatin 40 mg/m2 on days 2 and 9. The treatment was repeated every 28 days. Objective responses were seen in 7 (23%) patients, all achieving partial remissions. Median survival was 9 months for the entire group. Toxicity was mostly hematologic, with grade 3 leukopenia in 26% and grade 4 leukopenia in 55% of the patients. There were 4 treatment-related deaths that were attributable to severe leukopenia and sepsis. Because of the high toxicity and moderate response rate, this regimen is not superior to other less toxic regimens and cannot be recommended for the treatment of advanced gastric cancer outside of an investigational protocol.

AB - A phase II study was performed to determine the efficacy and toxicity of the etoposide, doxorubicin, cisplatin (EAP) regimen in the treatment of patients with advanced measurable gastric cancer in a multi-institutional cooperative group setting. Thirty-one evaluable patients with advanced measurable gastric adenocarcinoma were treated with etoposide 120 mg/m2 on days 3, 4, and 5, doxorubicin 20 mg/m2 on days 1 and 8, and cisplatin 40 mg/m2 on days 2 and 9. The treatment was repeated every 28 days. Objective responses were seen in 7 (23%) patients, all achieving partial remissions. Median survival was 9 months for the entire group. Toxicity was mostly hematologic, with grade 3 leukopenia in 26% and grade 4 leukopenia in 55% of the patients. There were 4 treatment-related deaths that were attributable to severe leukopenia and sepsis. Because of the high toxicity and moderate response rate, this regimen is not superior to other less toxic regimens and cannot be recommended for the treatment of advanced gastric cancer outside of an investigational protocol.

KW - Advanced gastric cancer

KW - Cisplatin

KW - Combination chemotherapy

KW - Doxorubicin

KW - Etoposide

UR - http://www.scopus.com/inward/record.url?scp=0029152092&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029152092&partnerID=8YFLogxK

U2 - 10.1097/00000421-199508000-00010

DO - 10.1097/00000421-199508000-00010

M3 - Article

C2 - 7625373

AN - SCOPUS:0029152092

VL - 18

SP - 318

EP - 324

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 4

ER -